Please assess the completion status of the following clinical trial:

Trial Title: Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide written informed consent~* Willing to comply with all study procedures and be available for the duration of the study~* Documented diagnosis of R-CECS determined with elevated compartmental pressure testing following lower extremity fascia release (fasciotomy or fasciectomy)~* Females of childbearing potential must have a negative urine pregnancy test prior to enrollment and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy.~  * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~    * Has not undergone a hysterectomy or bilateral oophorectomy; or~ * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~Exclusion Criteria:~* History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes~* Known neuromuscular disease~* Known pulmonary disease including but not limited to asthma, pneumonia, or upper respiratory tract infection~* Dysphagia~* Known cardiac disease including but not limited to congestive heart failure, arrhythmia, or history of myocardial infarction~* Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to enrollment~* Currently or have taken in the past medications that affect neuromuscular function, aminoglycosides, muscle relaxants, or other botulinum neurotoxin agents. Currently taking any blood-thinning medications including, but not limited to Plavix, Coumadin, Eliquis, Xarelto~* Women who are pregnant or breast-feeding~* Vulnerable populations~* Not suitable for study participation due to other reasons at the discretion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with R-CECS (Type: EXPERIMENTAL): Botox to be injected under standard palpatory technique into the affected lower leg compartment.

Based on this trial design, predict the completion outcome and termination type (if applicable).